Trióxido de Arsénico


 

REFERENCIAS

  • 1.- Eli G. Jones: Cancer.Its causes, symptoms and treatment (http://www.planetherbs.com/rarebooks/cancer/home.htm) (Siglo XIX)
  • 2.- Chernoviz, L.M. Guía Medica. Paris, 1904
  • 3.- Jing Y. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia. Leuk Lymphoma. 2004 Apr;45(4):639-48.
  • 4.- Tallmann MS. Curative therapeutic approaches to APL. Ann Hematol. 2004;83 Suppl 1:S81-2.
  • 5.- Vey N. Arsenic trioxide for the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2004 Mar;5(3):613-21.
  • 6.- Carter DE, Aposhian HV, Gandolfi AJ. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol Appl Pharmacol. 2003 Dec 15;193(3):309-34.
  • 7.- Adachi S, Leoni LM, Carson DA, Nakahata T. Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol. 2004;111(1-2):107-23.
  • 8.- Lengfelder E, Gnad U, Buchner T, Hehlmann R. Treatment of relapsed acute promyelocytic leukemia. Onkologie. 2003 Aug;26(4):373-9.
  • 9.- Estey EH. Treatment options for relapsed acute promyelocytic leukaemia.Best Pract Res Clin Haematol. 2003 Sep;16(3):521-34.
  • 10.- Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J. 2003 Jul;79(933):391-6.
  • 11.- Liu P, Han ZC. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int J Hematol. 2003 Jul;78(1):32-9.
  • 12.- List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, Greenberg P. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 2003 Aug;17(8):1499-507.
  • 13.- Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate.Leukemia. 2003 Aug;17(8):1454-63.
  • 14.- Ercilla Liceaga M, Andueza Granados K, Fernandez Gonzalez I, Barcia Romero MJ.[Arsenic trioxide in the treatment of acute promyelocytic leukaemia] Farm Hosp. 2003 Mar-Apr;27(2):93-100.
  • 15.- Mayorga J, Richardson-Hardin C, Dicke KA. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.Clin J Oncol Nurs. 2002 Nov-Dec;6(6):341-6.
  • 16.- Bachleitner-Hofmann T, Kees M, Gisslinger H. Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk Lymphoma. 2002 Aug;43(8):1535-40.
  • 17.- Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002 Oct;16(10):1959-73.
  • 18.- Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002 Jul 15;62(14):3893-903.
  • 19.- Bernstam L, Nriagu J. Molecular aspects of arsenic stress. J Toxicol Environ Health B Crit Rev. 2000 Oct-Dec;3(4):293-322.
  • 20.- Chao Niu , Hua Yan , Ting Yu , Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients Blood, Vol. 94 No. 10 (November 15), 1999: pp. 3315-3324
  • 21.- Soignet S. L., Maslak P., Wang Z-G., Jhanwar S., Calleja E., Dardashti L. J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D. A., Pandolfi P. P., Warrell R. P., Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339: 1341-1348, 1998
  • 22.- Soignet S. L., Frankel S. R., Douer D., Tallman M. S., Kantarjian H., Calleja E., Stone R. M., Kalaycio M., Scheinberg D. A., Steinherz P., Sievers E. L., Coutré S., Dahlberg S., Ellison R., Warrell R. P., Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol., 19: 3852-3860, 2001.
  • 23.- Murgo A. J. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist, 6 (Suppl. 2): 22-28, 2001.
  • 24. Mandelli F, Avvisati G, Lo Coco F. Advances in the understanding and management of acute promyelocytic leukemia. Rev Clin Exp Hematol. 2002 Mar;6(1):60-71;
  • 25. Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol. 2002 Apr;39(2 Suppl 1):8-1
  • 26.- Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002 Apr;39(2 Suppl1):3-7.
  • 27.- Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist. 2002;7 Suppl 1:1-13.
  • 28.- Zhao WL, Chen SJ, Shen Y, Xu L, Cai X, Chen GQ, Shen ZX, Chen Z, Wang ZY Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies. Leuk Lymphoma. 2001 Nov-Dec;42(6):1265-73.
  • 29.- Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996 Aug 1;88(3):1052-61
  • 30.- Zhang, P.., Wang, SY., Hu, XH et al.: trioxide arsenic treated 72 cases of acuye promyelocytic leucemia. Chi.J.Hematol., 1996: 17: 58-62
  • 31.- Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997 May 1;89(9):3354-60.
  • 32.- Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol. 1999 Dec;70(4):248-60.
  • 33.- Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001 Jul 15;98(2):266-71
  • 34.- Zhang X, Yang L, Qiao Z. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid. Zhonghua Nei Ke Za Zhi. 1999 Feb;38(2):113-5.
  • 35.- Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, Ferrara F. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica. 2002 May;87(5):485-9.
  • 36.- Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol. 2002 Aug;70(4):292-9
  • 37.- Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer. 2003 May 1;97(9):2218-24.
  • 38.- Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Rea D, Buzyn A, Tibi A, Lebbe G, Cimerman P, Chomienne C, Fermand JP, de The H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol. 2003 Jun 15;21(12):2326-34.
  • 39.- Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35.
  • 40. Soignet, SL, Maslak, P., Wang, Z-G: Complete remissión after treatment of acute promielocitic leukemia with arsenic trioxide. N.Eng.J. Med., 1998; 339, 1341-48
  • 41.- Sun HD., Ma., L., Hu XC, Zhang, TD: Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chi. J. Integrat of Chinese and Western Medicine, 1992, 12:170
  • 42. Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, Li X, Han X, Zhou J, Liu P. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide--an analysis of 242 cases] Zhonghua Xue Ye Xue Za Zhi. 2000 Feb;21(2):67-70.
  • 43.- Parmar S, Tallman MS. Acute promyelocytic leukaemia:a review. Expert Opin Pharmacother. 2003 Aug;4(8):1379-92.
  • 44.- Liu YF, Shen ZX, Chen X, Wang AH, Cao Q, Zhu YM, Chen SJ, Chen Z, Wang ZY. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)] Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):25-7.
  • 45. Hu X, Ma L, Hu N. [Ailing No. I in treating 62 cases of acute promyelocytic leukemia] Zhongguo Zhong Xi Yi Jie He Za Zhi. 1999 Aug;19(8):473-6.
  • 46.- Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol. 2001 Apr;66(4):274-9.
  • 47.-Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW, Kwong. YL. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol. 2002 Nov;58(8):521-6.
  • 48.- Au WY, Lie AK, Chim CS, Liang R, Ma SK, Chan CH, Mak YK, Chen YT, So CC, Yeung YM, Yip SF, Wong LG, Chan JC, Liu SY, Kwong YL. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol. 2003 May;14(5):752-7.
  • 49.- Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol. 2002 Apr;117(1):130-2.
  • 50.- Y. Shen, Shen, Z.Xm Yan Y., Studies on the clinical efficacy and pharmacokinetics of low dose arsenic trioxide in the treatment of relapsed acute promylocytic leukemia: a comparison with conventional dosage. Leukemia, (2001) 15: 735-741
  • 51.- Kumana CR, Au WY, Lee NSL, Kou M, Lam CW, Kwong YL. Systemic availability of oral arsenic-trioxide used for treatment of patients with haematological malignancies. Eur J Clin Pharmacol. 2002;58:521-526.
  • 52.- Carmosino I, Latagliata R, Avvisati G,Breccia M, Finolezzi E, Lo Coco,F. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004;89:615-617
  • 53.- ANTMAN KH. Introduction: The History of Arsenic Trioxide in Cancer Therapy. The Oncologist 2001;6(suppl 2):1-2
  • 54.. Rust DM , Soignet SL: Risk/Benefit Profile of Arsenic Trioxide. The Oncologist, Vol. 6, Suppl 2, 29-32, April 2001
  • 55. Soignet SL: Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. The Oncologist, Vol. 6, Suppl 2, 11-16, April 2001
  • 56.- Waxman, S, Anderson KC: History of the Development of Arsenic Derivatives in Cancer Therapy. The Oncologist 2001;6(suppl 2):3-10
  • 57.- Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia. 1998 Sep;12(9): 1383-91.
  • 58.- Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs. 2002 Aug;20(3):327-30.
  • 59.- Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 2002 Sep;16(9):1835-7
  • 60.- Wang Z-G, Rivi R, Delva L et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARa independent manner. Blood 1998;92:1497–1504
  • 61.- Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999;59:776–780.
  • 62.- Perkins C, Kim CN, Fang G et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x L . Blood 2000;95:1014–1022
  • 63.- Bachleitner-Hofmann T, Gisslinger B, Grumbeck E et al. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 2001;112:783–786.
  • 64.- Porosnicu M, Nimmanapalli R, Nguyen D et al. Co-treatment with As 2 O 3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 2001;15:772–778
  • 65.- König A, Wrazel L, Warrell RP Jr et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997;90:562–570
  • 66.- Ishitsuka K, Hanada S, Suzuki S et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998;103:721–728
  • 67.- Hermine O, Dombret H, Poupon J et al. Phase II trial of arsenic trioxide (As2O3 ) and combination of alpha interferon (IFN- a) and As2O3in patients with relapsed/refractory adult T-cell leukemia (ATL). Blood 2000;96(pt 1):342a.
  • 68.- Hu X-C, Zhang C, Li J-M et al. Use of arsenic trioxide in the treatment of chronic myelogenous leukemia: clinical efficacy in 34 patients. Program and Abstracts: Advances in Cancer Differentiation Therapy—A Meeting Combining the East and the West, Shanghai, China, October 13-14, 2000;14a
  • 69.- Hussein, M A: Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma. The Oncologist, Vol. 7, Suppl 1, 20-29, April 2002 .
  • 70.- Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation. 2004 Jan 6;109(1):26-9
  • Barbey JT, Pezzullo JC, Soignet SL Effect of arsenic trioxide on QT interval in patients with advanced malignancies.J Clin Oncol. 2003 Oct 1;21(19):3609-15
 
Monografía revisada el 17 de Diciembre de 2010